2011 - Transplantomics and Biomarkers in Transplantation

This page contains exclusive content for the member of the following sections: TTS. Log in to view.

Biomarkers to Improve Patient Management in Solid Organ Transplantation

2.1 - Results from the Biomarkers/Gene Expression Arrays Arisen from RISET

Presenter: Birgit, Sawitzki, Berlin, Germany
Authors: Birgit Sawitzki

Results from the Biomarkers/Gene Expression Arrays Arisen from RISET

Birgit Sawitzki, Charité University Medicine, Berlin, Germany

Learning Objectives:

1. What do we need to monitor during drug minimization trials?
2. Which questions should the immune monitoring help to answer?
3. Which cellular players and compartments should be studied?
4. Examples of RISET test results from selected clinical trials

Currently, many organ transplant patients receive more immunosuppression than required subsequently suffering from severe side effects such as cancer, infections and cardiovascular diseases.In contrast other transplant patients develop signs of chronic transplant damage due to insufficient immunosuppression. Thus there is an urgent need for tailor made immunosuppression according to the actual immune reactivity.

The ultimate goal of the European network RISET “Reprogramming the Immune System for the Establishment of Tolerance” was to develop safe and efficient therapies and diagnostic tools to enable drug minimization in transplant patients. We have implemented cellular assays, cell phenotyping as well as genomic and proteomic assays. A critical point was the extensive methodological validation and standardisation of assays in the performing core labs. Using this approach the RISET consortium has successfully developed new tests and defined molecular signatures of “tolerance” and rejection. Examples for assay standardisation and test results will be presented during the talk. The critical next steps are now to validate the test and assay performance in large multi center trials so that they can be introduced into regular immune diagnostics and will be accepted as surrogate markers of graft acceptance or ejection.

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.



Staff Directory


The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6